KVD900 600 mg for Hereditary Angioedema

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Hereditary AngioedemaKVD900 600 mg - Drug
Eligibility
12 - 17
All Sexes
What conditions do you have?
Select

Study Summary

This trial is looking at how a new drug affects teenagers with Hereditary Angioedema.

Eligible Conditions
  • Hereditary Angioedema

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: Up to 6 hours after IMP administration

Hour 6
Pharmacokinetics - AUC
Pharmacokinetics - Cmax
Pharmacokinetics - Tmax

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

1 Treatment Group

KVD900 600 mg
1 of 1

Experimental Treatment

12 Total Participants · 1 Treatment Group

Primary Treatment: KVD900 600 mg · No Placebo Group · Phase 3

KVD900 600 mg
Drug
Experimental Group · 1 Intervention: KVD900 600 mg · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 6 hours after imp administration

Who is running the clinical trial?

KalVista Pharmaceuticals, Ltd.Lead Sponsor
9 Previous Clinical Trials
737 Total Patients Enrolled
Study DirectorStudy DirectorKalVista Pharmaceuticals, Ltd.
1,070 Previous Clinical Trials
475,566 Total Patients Enrolled

Eligibility Criteria

Age 12 - 17 · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You must provide a legally authorized representative (LAR) when you are 18 years or older.